instruction stringlengths 1.05k 19.6k | output stringlengths 45 233 | prompt stringclasses 1
value |
|---|---|---|
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse', 'Brief Summary': 'The purpose of this study is to ... | {'Arm - Disease - Biomarker': 'Exclude: PD-1, PD-L1, PD-L2, CTLA-4'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.', 'Brief Summary': 'Hormone Receptor (HR)-positive/Human Epidermal G... | {'Arm - Disease - Biomarker': 'Include: HR+, HER2- Exclude: HER2+'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.', 'Brief Summary': 'Hormone Receptor (HR)-positive/Human Epidermal G... | {'Arm - Disease - Biomarker': 'Include: HR+, HER2- Exclude: HER2+'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)', 'Brief Summary': 'The purpose of this study is to ev... | {'Arm - Disease - Biomarker': 'Include: EGFR mutation, specifically either DEL19 or L858R, confirmed acquired T790M mutation'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)', 'Brief Summary': 'The purpose of this study is to ev... | {'Arm - Disease - Biomarker': 'Include: EGFR mutation, specifically either DEL19 or L858R, confirmed acquired T790M mutation'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer', 'Brief Summary': 'The purpose of this study is to: (a) characterize the safety and tolerability of and to ide... | {'Arm - Disease - Biomarker': 'Include: Fibroblast growth factor receptor (FGFR) gene alterations '} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer', 'Brief Summary': 'The purpose of this study is to: (a) characterize the safety and tolerability of and to ide... | {'Arm - Disease - Biomarker': 'Include: Fibroblast growth factor receptor (FGFR) gene alterations '} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer', 'Brief Summary': 'This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -... | {'Arm - Disease - Biomarker': 'Include: EGFR mutation (Exon 19 deletion, T790M, or L858R) on tumor samples'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer', 'Brief Sum... | {'Arm - Disease - Biomarker': 'Include: HR-Positive, HER2-Negative'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer', 'Brief Sum... | {'Arm - Disease - Biomarker': 'Include: HR-Positive, HER2-Negative'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer', 'Brief Summary': 'This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 in patients with locally advanced or metastatic breast cancer (MBC).', 'Condition': 'Metastatic Breast Cancer Locally Advanced... | {'Arm - Disease - Biomarker': 'Include: HER2-Negative, HR-Positive Exclude: HER2-positive'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer', 'Brief Summary': 'This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 in patients with locally advanced or metastatic breast cancer (MBC).', 'Condition': 'Metastatic Breast Cancer Locally Advanced... | {'Arm - Disease - Biomarker': 'Include: HER2-Negative, HR-Positive, Regardless of HER3 expression Exclude: HER2-positive'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer', 'Brief Summary': 'This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 in patients with locally advanced or metastatic breast cancer (MBC).', 'Condition': 'Metastatic Breast Cancer Locally Advanced... | {'Arm - Disease - Biomarker': 'Include: HER2-Positive Exclude:HER2-Negative'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C', 'Brief Summary': 'A Phase 3 Study to Compare AMG 510 with Docetaxel in... | {'Arm - Disease - Biomarker': 'KRASG12C mutated'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C', 'Brief Summary': 'A Phase 3 Study to Compare AMG 510 with Docetaxel in... | {'Arm - Disease - Biomarker': 'KRASG12C mutated'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', 'Brief Summary': 'This is a Phase Ib/II, open-label, multicenter, randomized umbrella... | {'Arm - Disease - Biomarker': 'Include: PD-L1'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
{'Official Title': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1', 'Brief Summary': 'This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advance... | {'Arm - Disease - Biomarker': 'Include: KRAS G12C mutation'} | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... |
End of preview. Expand in Data Studio
No dataset card yet
- Downloads last month
- 7